Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma. (1st October 2021)

• Record Type: Journal Article
• Authors: Bastos‐Oreiro, Mariana; Ortiz, Javier; Pradillo, Virginia; Salas, Eduardo; Marínez‐Laperche, Carolina; Muñoz, Andrés; Buño, Ismael; Diéz‐Martin, José Luis; Soria, Jose Manuel; Pascual Izquierdo, Cristina
• Is Part Of: Cancer medicine. Volume 10:Number 21(2021)
• Page Start: 7585
• Page End: 7592
• Publication Date: 2021-10-01
• Subjects: genetic risk score -- lymphoma complications -- thromboembolism risk; 616.994005
• DOI: 10.1002/cam4.4280
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Background: The incorporation of genetic variables into risk scores for predicting venous thromboembolic events (VTE) could improve their capacity to identify those patients for whom thromboprophylaxis would be most beneficial. Proof‐of‐concept of this is provided by the TiC‐ONCO score for predicting the risk of VTE in patients with solid tumours. Our aim was to develop a similarly improved tool—the TiC‐LYMPHO score—for predicting VTE in patients with lymphoma. Methods: In a retrospective observational study of 208 patients with lymphoma, 31 (14.9%) were found to have experienced an episode of VTE either at the time of diagnosis or over the next 6 months. Clinical variables associated with VTE, determined via logistic regression analysis, plus the same genetic variables included in the TiC‐ONCO score, were used to build the TiC‐LYMPHO score algorithm. The sensitivity, specificity, predictive values and AUC of the TiC‐LYMPHO, the Khorana and ThroLy scores were compared in the same population. Results: The TiC‐LYMPHO score showed a significantly higher AUC, sensitivity and NPV (0.783, 95.35% and 97.98% respectively) than the other scores. The ThroLy score showed a significantly higher specificity (96.43% vs. 54.49%; p < 0.0001) and PPV (37.50% vs. 26.36%; p = 0.0147) than the TiC‐LYMPHO score, whereas its AUC, sensitivity and NPV were significantly lower (0.579, 19.35% and 86.48%, respectively). Conclusion: These results show that by incorporating genetic and clinical data into VTE risk assessment, the TiC‐LYMPHO score can categorize patients with lymphoma better in terms of their risk of VTE and allow individualized thromboprophylaxis to be prescribed. Abstract : This is a single‐centre observational study that analyses the utility of combining genetic and clinical variables in a thromboembolism risk score in patients with lymphoma. The TiC‐LYMPHO score showed a significantly higher AUC, sensitivity and NPV (0.783%, 95.35% and 97.98%, respectively) than the other scores. These results show that by incorporating genetic and clinical data into VTE risk assessment, the TiC‐LYMPHO score can categorize patients with lymphoma better in terms of their risk of VTE and allow individualized thromboprophylaxis to be prescribed.